InvestorsHub Logo
Followers 2543
Posts 250732
Boards Moderated 34
Alias Born 05/06/2014

Re: None

Thursday, 12/10/2015 10:22:42 PM

Thursday, December 10, 2015 10:22:42 PM

Post# of 512
$RLMD EDISON EQUITY RESEARCH: RELMADA THERAPEUTICS

Source: InvestorsHub NewsWire
EDISON EQUITY RESEARCH: RELMADA THERAPEUTICS - ACHIEVED PROOF-OF-CONCEPT FOR BUTAB

Today, Relmada announced that its pharmacokinetic (PK) study in 30 healthy volunteers for BuTab, its orally ingestible formulation of buprenorphine, was successful and achieved safe and effective blood levels of the drug. As a reminder, currently none of the marketed forms of buprenorphine (which have >$1bn annual sales in the US combined) can be swallowed as they are sublingual, buccal or patch formulations.

Relmada is an emerging pharmaceutical product company focusing on the treatment of pain. It has four key products, LevoCap ER, d-Methadone, BuTab ER and MepiGel that focus on large and lucrative segments of the pain market.

To view our full report, please click here.

Click here to view all of Edison Investment Research’s published reports.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RLMD News